Glycom A/s

Other

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Universite Paris Cité

Pierre Chassagne

Martin Matwiejuk

Markus Jondelius Hederos

Gyula Dekany

Nikolay Khanzhin

Benjámin Podányi

Györgyi Osztrovszky

Philippe J Sansonetti

Elise Champion

Markus Hederos

Francois Traincard

Laurence Mulard

Ferenc Horváth

Armelle Phalipon

Farida Nato

Pauline Peltier-Pain

Dóra Molnár-Gábor

Agnese Maggi

Christophe Pain

Nicolas Fierfort

Dóra Molnàr-Gàbor

Niels Banke

Markus Hederos Jondelius

François Traincard

The invention relates to a method for selective crystallization of 2'-fucosyllactose (2′-FL) from an aqueous solution comprising 2′-FL and one or more other fucosylated carbohydrates by adding acetic acid to the solution. The aqueous solution is separated from an aqueous culture medium prior to crystallization.

Separation of 2'-FL from a fermentation broth

It is provided i) an amorphous carbohydrate with improved chemical stability and/or physical features, ii) a method for producing an amorphous carbohydrate with improved chemical stability and/or physical features, and iii) a method for improving the chemical stability and/or the physical features of an amorphous carbohydrate.

Amorphous mixture comprising a neutral mono- or oligosaccharide and an acidic non-carbohydrate component

The invention relates to crystalline polymorphs of lacto-N-tetraose (LNT) and methods for making the same for use in pharmaceutical compositions, nutritional formulations and food supplements.

Crystalline forms of LNT

The present invention relates to a method of removing residual organic solvent from crystalline oligosaccharides by the use of water vapour as well as the pharmaceutically and nutritionally suitable crystalline oligosaccharides obtained by said method.

Method for removing residual organic solvent from a crystalline oligosaccharide

The invention relates to a method for obtaining an N-acetylglucosamine containing neutral oligosaccharide from a fermentation broth, wherein said oligosaccharide is produced by culturing a genetically modified microorganism capable of producing said oligosaccharide from an internalized carbohydrate precursor, comprising the steps of: i) ultrafiltration (UF), preferably to separate biomass from the broth, ii) nanofiltration (NF), preferably to concentrate said oligosaccharide in the broth and/or reduce an inorganic salt content of the broth, and iii) treating the broth with an ion exchange resin, preferably to remove charged materials, and/or subjecting the broth to chromatography, preferably to remove hydrophobic impurities.

Separation of oligosaccharides from fermentation broth

The present invention relates to a method for separating sialylated oligosaccharides from a fermentation broth in which they are produced by a genetically modified microorganism The separation comprises the steps of: i) ultrafiltration; ii) nano-filtration; iii) optionally, activated charcoal treatment; and iv) treatment with strong anion and/or cation exchange resin.

The invention relates to a method for selective crystallization of 2'-FL from an aqueous solution comprising 2&#x2032;-FL and one or more other fucosylated carbohydrates by adding acetic acid to the solution.

Crystalline difucosyllactose, useful in a pharmaceutical composition and a nutritional composition, is disclosed.

Crystalline difucosyllactose

Crystalline pLNnH, useful in a pharmaceutical or nutritional composition, is disclosed.

Crystalline HMO

The present invention relates to a conjugate comprising an oligo- or polysaccharide selected from the group consisting of: (X)-{BCDA}-(Y)(X)-{CDAB}-(Y)(X)-{DABC}-(Y)(X)-{ABCD}n-(Y)wherein A, B, C, D, X and Y, x, y and n are as defined in claim, said oligo- or polysaccharide being bound to a carrier.

Glycoconjugates and their use as potential vaccines against infection by

An achemo-enzymatic synthesis of oligosaccharides of formula 1 is presented wherein R is selected from &#x2014;OH, &#x2014;N 3 and &#x2014;OR 6 wherein R 6 is selected from allyl optionally substituted by one or more methyl, propargyl optionally substituted by one or more methyl, 2-trimethylsilyl-ethyl, &#x2014;(CH 2) n &#x2014;NH 2 and &#x2014;(CH 2) n &#x2014;N 3 wherein integer n is to 10, preferably 2 or 3, R is selected from sialyl moiety, &#x2014;SO 3 H and &#x2014;CH(R)&#x2014;COOH wherein R is selected from H, alkyl and benzyl, R 2 is selected from H and fucosyl, R 3 is selected from H and sialyl, R 4 is selected from H and fucosyl, provided that at least one of R 3 and R 4 is H, and A is a divalent carbohydrate linker, having important biological activities and significant commercial value for the pharmaceutical and food industry.

Growing community of inventors

Beaumont, France

Pierre Chassagne